the same scientific seminars and symposiums as academic and industry scientists, to learn about new methods and technologies, and to connect, network, and establish collaborations. Related to this is the need to work collaboratively across government agencies and to leverage those relationships.

While Pillar 2 is just “scraping the tip of the iceberg,” the MCM enterprise is moving in the right direction. The processes that have been set up for internal project proposal reviews, for example, engage all of the MCM enterprise partners. This peer-review process increases the visibility and awareness of partners, thereby creating greater potential for partnerships and collaboration with FDA and across the MCM enterprise as a whole.

The success of the FDA MCM initiative will not be dependent solely upon FDA’s efforts, Hu-Primmer concluded, explaining that it depends on everyone working together, from informal collaborations to competitive grants and contracts, and all options in between.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement